Ftse Mib
34.169,71
-1,41%
DAX
18.473,29
-1,13%
S&P 500
5.278,56
-0,52%
NASDAQ
16.960,90
-0,35%
Bitcoin
67.651,50
-0,94%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Werewolf Therapeutics Inc (HOWL) Werewolf Therapeutics Inc (HOWL) Notizie

HOWL

Werewolf Therapeutics (HOWL)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:HOWL
DataOraFonteTitoloSimboloCompagnia
28/05/202422:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HOWLWerewolf Therapeutics Inc
25/05/202401:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
23/05/202423:00GlobeNewswire Inc.Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
03/05/202413:00GlobeNewswire Inc.Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
24/04/202416:05GlobeNewswire Inc.Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
23/04/202414:00GlobeNewswire Inc.Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
05/04/202422:30GlobeNewswire Inc.Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
04/04/202422:30GlobeNewswire Inc.Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
07/03/202413:22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:HOWLWerewolf Therapeutics Inc
07/03/202413:15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:HOWLWerewolf Therapeutics Inc
07/03/202413:00GlobeNewswire Inc.Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
06/03/202414:00GlobeNewswire Inc.Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
05/03/202422:30GlobeNewswire Inc.Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024NASDAQ:HOWLWerewolf Therapeutics Inc
09/02/202422:35Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:HOWLWerewolf Therapeutics Inc
05/01/202401:13Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:HOWLWerewolf Therapeutics Inc
04/01/202422:05GlobeNewswire Inc.Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of DirectorsNASDAQ:HOWLWerewolf Therapeutics Inc
22/11/202313:00GlobeNewswire Inc.Werewolf Therapeutics to Present at the Evercore ISI HealthCONx ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
14/11/202322:25GlobeNewswire Inc.Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
03/11/202312:00GlobeNewswire Inc.Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
31/10/202314:00GlobeNewswire Inc.Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
27/09/202315:00GlobeNewswire Inc.Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingNASDAQ:HOWLWerewolf Therapeutics Inc
11/09/202322:05GlobeNewswire Inc.Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124NASDAQ:HOWLWerewolf Therapeutics Inc
05/09/202322:05GlobeNewswire Inc.Werewolf Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:HOWLWerewolf Therapeutics Inc
24/08/202320:00AllPennyStocks.comBiotech Soars On New Price Target And Analyst RatingNASDAQ:HOWLWerewolf Therapeutics Inc
10/08/202313:10GlobeNewswire Inc.Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:HOWLWerewolf Therapeutics Inc
10/08/202313:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HOWLWerewolf Therapeutics Inc
27/06/202322:35Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:HOWLWerewolf Therapeutics Inc
23/06/202323:10Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:HOWLWerewolf Therapeutics Inc
01/06/202313:00GlobeNewswire Inc.Werewolf Therapeutics to Present at the Jefferies Healthcare ConferenceNASDAQ:HOWLWerewolf Therapeutics Inc
11/05/202313:08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:HOWLWerewolf Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:HOWL

La tua Cronologia

NASDAQ
MDIAV
Mediaco
KUCN
CANETH
CanYaCoin
LSE
ITPE
Ish $tips Eur-h
COIN
I0CBTC
AQEU
FROO
Frontline
NASDAQ
GAFFCX
GoalPath Fi360 2050 Cons...
BINA
CYBERETH
CyberConnect
ASX
CBAIOA
DBI
I1A2
Xtr MSCI World ESG Scree...
KUCN
JAMETH
Geojam
EU
A886T
A886T
BIT
F07688
Vontobel Financial Produ...
BIT
MUSRI
Easy Msci Emu Sri S-seri...
COIN
PLEEETH
Plethori
TSX
MNY
Purpose Cash Management
BIT
UB26GS
UniCredit Bank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network